Infectious side effects of cancer treatment in children. Clinical and genetic aspects
PhD ceremony: Ms. E.M. te Poele, 14.30 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Infectious side effects of cancer treatment in children. Clinical and genetic aspects
Promotor(s): prof. E.S.J.M de Bont, prof. W.A. Kamps
Faculty: Medical Sciences
Chemotherapy has significantly improved the survival of children with cancer. One of the side effects of chemotherapy is the inhibited production of white blood cells. This effect predisposes for infections and infectious complications. Therefore, fever during neutropenia (lack of a specific type of white blood cells) is treated with intravenous antibiotics. The first part of this thesis deals with clinical issues. We examined the possibilities for a better risk assessment of fever during neutropenia to prevent overtreatment of patients with a low risk for bacterial infections. This cost-efficient approach may contribute to a better quality of life.
Subsequently, we studied the number of infectious deaths during the ALL-9 protocol (treatment for acute lymphoblastic leukemia (ALL) in children). We found an increase in the number of infectious deaths compared to previous protocols. This is most probably caused by repeated, prolonged treatment with the drug Dexamethasone in ALL-9. Furthermore, the use of Pegfilgrastim was evaluated. This medicine may be administered to reduce chemotherapy induced neutropenia. Pegfilgrastim is only registered for use in adults, but also seems to be safe for children. Lastly, we studied the mortality of non-elective ICU admissions in children with cancer. One of the conclusions of this study is that the survival of these children increased significantly. The second part of this thesis concerns several studies of genetic variants and the risk of developing ALL and (fever during) neutropenia. It was concluded that particular genetic variants that are associated with atopy have an inverse association with ALL.
Last modified: | 13 March 2020 01.02 a.m. |
More news
-
29 November 2023
UMCG opent nieuwe faciliteit voor microbioomonderzoek 
Vandaag opent het UMCG de Groningen Microbioom Hub: een nieuwe faciliteit met state-of-the-art technologie waarin alle UMCG-expertise op het gebied van microbioomonderzoek samenkomt. Dit zorgt voor unieke mogelijkheden in onderzoek en maakt nieuwe...
-
28 November 2023
Science: more exciting than showbiz
Science often seems very complicated. Most people probably don't really know what researchers do, and what it takes to make a breakthrough. That is why it is important to keep the general public informed of what is happening in science, says Iris...
-
13 November 2023
UMCG beantwoordt vragen patiënten met hulp van AI
Het UMCG zet kunstmatige intelligentie (artificial intelligence, afgekort AI) in om zorgverleners te helpen bij het beantwoorden van schriftelijke vragen van patiënten. Dit gebeurt in samenwerking met andere ziekenhuizen vanuit de EPIC Nederlandse...